Inadequate funding is likely to hinder plans by Nigerian Institute for Pharmaceutical Research and Development to get a major drug, Niprisan, listed by Nigeria's food and drug agency this year.
The institute says it is short of funding, despite a recent N35 million increase in budgetary allocation this year. It is an increase from a previous N52 million yearly budget to N87 million this year.
...
AllAfrica Subscription Content
You must be an allAfrica.com subscriber for full access to certain content.
You have selected an article from the AllAfrica archive, which requires a subscription. You can subscribe by visiting our subscription page. Or for more information about becoming a subscriber, you can read our subscription and contribution overview.
For information about our premium subscription services:
You can also freely access - without a subscription - hundreds of today's top Africa stories and thousands of recent news articles from our home page »
Already a subscriber? Sign in for full access to article